Disclaimer: VFC has no affiliation with Titan Pharmaceuticals or with any third parties associated with the companies. VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog. VFC does not offer advice or investment services and nothing you read here should be construed as such. VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table. #AhYeah.
Shares of Titan Pharmaceuticals (TTNP) are also worth watching this week.
Titan is the proprietary owner and distributor of Probuphine, an implant a slow-releasing buprenorphine implant based on the company's ProNeura technology to treat opioid addiction.
Opioid addiction is a scourge of global society, helmed by not only the cartels and criminals, but by the biggest drug-pushers in the world - the pharmaceutical industry. The amount of people dying from drug overdose rivals what we've seen from Covid19, but with less the fanfare. Titan pharmaceuticals is in a prime position to take advantage of some of the treatment market share, especially since the Probuphine implant is slow-releasing and alleviates the threat of overdose.
Click 'Read more' below the ad to continue! Great travel deals and discount codes with the link below! Get ready for that post-covid travel!